Invesaro

Stocks Health care INCY

NASDAQ · Health care

Incyte Corp (INCY)

Incyte Corp brought in $5.4B of revenue over the twelve months to March 31, 2026, up 21.5% from a year earlier. Net income was $1.4B, a net margin of 26.7%. At March 31, 2026 it held $3.5B in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 28, 2026.

Price
$123.89
-0.44% on the day · September 25, 2026
52-week range $82.52 to $132.60
Market cap
$25.1B
Revenue (last 12 months)
$5.4B
+21.5% year on year
Net margin
26.7%
P/E
19.3
on FY2025 diluted EPS

What Incyte Corp does

Incyte Corp is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NASDAQ under the ticker INCY.

Revenue and profit by year

Revenue
FY18: $1.9B $1.9B FY18FY19: $2.2B $2.2B FY19FY20: $2.7B $2.7B FY20FY21: $3B $3B FY21FY22: $3.4B $3.4B FY22FY23: $3.7B $3.7B FY23FY24: $4.2B $4.2B FY24FY25: $5.1B $5.1B FY25
Net income
FY18: $109.5M $109.5M FY18FY19: $446.9M $446.9M FY19FY20: -$295.7M -$295.7M FY20FY21: $948.6M $948.6M FY21FY22: $340.7M $340.7M FY22FY23: $597.6M $597.6M FY23FY24: $32.6M $32.6M FY24FY25: $1.3B $1.3B FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$5.1B$1.5B$1.3B$6.41n/a
2024$4.2B$61.4M$32.6M$0.15n/a
2023$3.7B$620.5M$597.6M$2.65n/a
2022$3.4B$579.4M$340.7M$1.52$892.1M
2021$3B$585.8M$948.6M$4.27$568.5M
2020$2.7B-$263.7M-$295.7M-$1.36-$312M

Latest SEC filings

What Incyte Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 31, 2026
    Other event 8-K
  2. July 28, 2026
    Quarterly report 10-Q · period to June 30, 2026
  3. July 28, 2026
    Quarterly results 8-K
  4. July 6, 2026
    Other event 8-K
  5. June 22, 2026
    Other event 8-K
  6. June 9, 2026
    Shareholder vote results 8-K
  7. June 8, 2026
    Other event 8-K
  8. May 27, 2026
    Additional proxy material DEFA14A
  9. May 14, 2026
    Passive stake changed SCHEDULE 13G/A
  10. May 11, 2026
    Activist stake changed SCHEDULE 13D/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 24, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about INCY

What does Incyte Corp do?

Incyte Corp is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NASDAQ under the ticker INCY.

Is Incyte Corp profitable?

Yes. Over the twelve months to March 31, 2026 it reported net income of $1.4B on revenue of $5.4B, a net margin of 26.7%.

How much revenue does Incyte Corp make?

Over the twelve months to March 31, 2026 Incyte Corp reported revenue of $5.4B. That is 21.5% more than a year earlier.

When did Incyte Corp last report?

Its most recent periodic report is the quarterly report (10-Q) filed on July 28, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 24, 2026.

Similar companies

IQV
Iqvia Holdings Inc.
ICLR
Icon PLC
CRL
Charles River Laboratories International, Inc.
MEDP
Medpace Holdings, Inc.
NOTVQ
Inotiv, Inc.
NRC
Nrc Health

Follow INCY

Get an email when Incyte Corp files with the SEC: results, executive changes, material agreements and annual reports.

Follow INCY: get an email when it files

Where the numbers come from

Financial figures are the values Incyte Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.